Results 221 to 230 of about 21,140 (245)

NALTREXONE IN THE TREATMENT OF ALCOHOLISM

Annual Review of Medicine, 1997
▪ Abstract  Alcoholism affects nearly 12.5 million Americans and is responsible for annual costs of over $130 billion from loss of job productivity, deleterious health effects, and direct treatment expenses. Research on treating alcoholism from the standpoint of relapse prevention using psychosocial interventions alone has produced only modest results.
Weinrieb Rm, Charles P. O'Brien
openaire   +3 more sources

Comparison of two naltrexone treatment programs: naltrexone alone versus naltrexone plus behavior therapy.

NIDA research monograph, 1976
During a period of one year naltrexone was given to twenty-nine subjects. Fifteen of these subjects concurrently participated in a comprehensive behavior therapy program. The subjects in this naltrexone/behavior therapy group were maintanine on naltrexone for nearly twice as long as naltrexone group clients who received no therapy.
Michael Glazer, Beverly McCleave, Edward J. Callahan, Richard Arias, Richard A. Rawson   +4 more
openaire   +3 more sources

Naltrexone et tramadol

Toxicologie Analytique et Clinique, 2017
Objectif Rapporter un deces dans lequel l’association tramadol–naltrexone est peut-etre impliquee. Description du cas Un homme de 43 ans, alcoolo-dependant, subit une arthrodese de l’arriere du pied droit suite a un traumatisme des 2 chevilles 6 ans auparavant, a l’issue de laquelle il recoit une prescription de TOPALGIC® 100 (2/J) (J–10 avant le ...
François Paraf, Fanny Moreau, Jean-Michel Gaulier, C. Coeffeteau, L. Carton   +4 more
openaire   +2 more sources

Assessment of naltrexone in the treatment of schizophrenia

Psychopharmacology, 1981
Naltrexone, a long acting opiate antagonist, and placebo were administered to eight schizophrenics in doses of 200 mg per day for 1 week in a double-blind, crossover design. No improvement was noted, and no side effects resembling the opiate withdrawal syndrome with naltrexone were found. Naltrexone does not appear to alter schizophrenic symptomatology.
Michael Rosenblatt, Robert H. Gerner, Michael J. Gitlin   +2 more
openaire   +3 more sources

Erectile Function and Naltrexone

Annals of Internal Medicine, 1986
Excerpt To the editor: The male patient with erectile dysfunction who has had normal findings on urologic, endocrinologic, and hemodynamic evaluations is usually referred for sexual counseling with...
openaire   +2 more sources

Naltrexone-3-salicylate (a prodrug of naltrexone): synthesis and pharmacokinetics in dogs.

Pharmaceutical research, 1988
Naltrexone-3-salicylate (3), a prodrug of naltrexone (1), was prepared by a simple procedure from naltrexone-3-acetylsalicylate (2). The plasma (dog and human) hydrolysis half-life of 3 was found to be approximately 30 min. Compound 2 was previously shown to hydrolyze in dog and human plasma with a fast deacetylation step to 3, followed by slower ...
Munir A. Hussain, Eli Shefter
openaire   +3 more sources

▼Naltrexone/bupropion for obesity

Drug and Therapeutics Bulletin, 2017
▼ Naltrexone/bupropion (Mysimba - Orexigen Therapeutics Ireland Limited) is a fixed-dose combination product for the treatment of adults who are obese or overweight with at least one weight-related comorbidity, as an adjunct to diet and lifestyle modifications.
openaire   +2 more sources

Extended-Release Intramuscular Naltrexone

Drugs, 2006
An extended-release intramuscular formulation of naltrexone that provides sustained release of the drug over a 28-day period has been developed with the aim of improving treatment adherence in patients treated with naltrexone for alcohol dependence.
Tracy Swainston Harrison, Susan J Keam, Greg L. Plosker   +2 more
openaire   +3 more sources

Naloxone and Naltrexone

2019
Naloxone is a highly specific, high-affinity opioid antagonist used to reverse the effects of opioids. It is available in several formulations for convenient administration by medical trained personnel and by lay persons in the ambulatory setting. Naltrexone is available orally or by long acting intramuscular injection for alcohol or opioid dependence ...
openaire   +2 more sources

Naltrexone and Dysphoria: Fact or Myth?

The American Journal on Addictions, 2002
Naltrexone is an opiate antagonist used as a pharmacologic adjuvant for the treatment of opiate and alcohol addiction. It has been hypothesized that naltrexone blocks the stress‐response and well‐being effects associated with opioid peptides. This raises the clinical concern that naltrexone may cause dysphoria.
Michael McCann, Karen Miotto, B A Janice Basch, Walter Ling, Richard A. Rawson   +4 more
openaire   +3 more sources